Glycoworks rapifluor ms n glycan kit
The GlycoWorks RapiFluor-MS N-Glycan Kit is a laboratory product that enables the fluorescent labeling of N-glycans derived from glycoproteins for analysis using mass spectrometry. The kit provides the necessary reagents and protocols to facilitate the sample preparation and labeling process.
Lab products found in correlation
19 protocols using glycoworks rapifluor ms n glycan kit
Enzymatic Release and RFMS Labeling of N-Glycans
IgG N-Glycan Analysis by RapiFluor-MS
N-Glycan Profiling of Plasma Membrane
N-Glycan Oligosaccharide Analysis by HPLC-MS
Site-specific glycosylation analysis was also performed as described previously.52 (link)
IgG N-Glycan Analysis by RapiFluor-MS
IgG Isolation and N-Glycan Analysis
N-Glycan Profiling of Secretome Proteins
N-Glycan Analysis of Secretome
Example 3
N-glycan analysis was performed with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. In this case 12 μl of 10× concentrated (MWCO filtered, Amicon Ultra-15, Merck, Darmstadt, Germany) secretome or purified protein sample were used for each. Labeled N-Glycans were analyzed by a LC-MS system using a Thermo Ultimate 3000 HPLC with fluorescence detector coupled on-line to a Thermo Velos Pro Iontrap MS. Separation gradient 30% to 43% buffer and MS was run in positive mode.
N-Glycan Profiling of Therapeutic Proteins
Automated N-glycan Release and Labeling for Mass Spectrometry
Andrew Alliance pipetting robot (Geneva, Switzerland) as described previously.19 (link) Briefly, 10 µL of diluted infliximab sample was loaded to a 96-well sample plate.
Reagents including RapiGest surfactant, Rapid PNGase F enzyme, and RFMS
labeling reagent were used for protein denaturation, N-glycan release, and labeling,
respectively, by following a modified protocol in the GlycoWorks RapiFluor-MS
N-Glycan Kit Care and Use Manual (p/n 715004793).19 (link) A total of 48 released N-glycan samples were prepared, including 12 samples from
batch 1 of innovator infliximab, 6 samples from each of the other three batches of
innovator infliximab, 6 samples for each of two batches of biosimilar infliximab, and 6
samples from a blank control solution. After the glycan labeling protocol was completed,
0.25 pmol of a high mannose glycan standard (Waters) was spiked into each of six released
glycan samples prepared from innovator batch 1. This group of samples was used to evaluate
the capability of the workflow to capture the relative abundance changes in glycans across
samples.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!